ATE409474T1 - Tryptamin-derivative und analoge verbindungen, und pharmazeutische formulationen daraus - Google Patents

Tryptamin-derivative und analoge verbindungen, und pharmazeutische formulationen daraus

Info

Publication number
ATE409474T1
ATE409474T1 AT01974651T AT01974651T ATE409474T1 AT E409474 T1 ATE409474 T1 AT E409474T1 AT 01974651 T AT01974651 T AT 01974651T AT 01974651 T AT01974651 T AT 01974651T AT E409474 T1 ATE409474 T1 AT E409474T1
Authority
AT
Austria
Prior art keywords
pharmaceutical formulations
analogue compounds
tryptamine derivatives
tryptamine
derivatives
Prior art date
Application number
AT01974651T
Other languages
German (de)
English (en)
Inventor
Nava Zisapel
Moshe Laudon
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Application granted granted Critical
Publication of ATE409474T1 publication Critical patent/ATE409474T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01974651T 2000-10-03 2001-09-25 Tryptamin-derivative und analoge verbindungen, und pharmazeutische formulationen daraus ATE409474T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL138825A IL138825A (en) 2000-10-03 2000-10-03 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds

Publications (1)

Publication Number Publication Date
ATE409474T1 true ATE409474T1 (de) 2008-10-15

Family

ID=11074694

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01974651T ATE409474T1 (de) 2000-10-03 2001-09-25 Tryptamin-derivative und analoge verbindungen, und pharmazeutische formulationen daraus

Country Status (39)

Country Link
US (2) US6780884B2 (enExample)
EP (1) EP1331935B1 (enExample)
JP (1) JP2004533986A (enExample)
KR (1) KR100855385B1 (enExample)
CN (1) CN100518735C (enExample)
AR (1) AR035587A1 (enExample)
AT (1) ATE409474T1 (enExample)
AU (1) AU9416201A (enExample)
BG (1) BG107759A (enExample)
BR (1) BR0114464A (enExample)
CA (1) CA2423628C (enExample)
CL (1) CL2001002303A1 (enExample)
CR (1) CR6968A (enExample)
CY (1) CY1110417T1 (enExample)
CZ (1) CZ301098B6 (enExample)
DE (1) DE60136003D1 (enExample)
DK (1) DK1331935T3 (enExample)
EA (1) EA005918B1 (enExample)
EE (1) EE05192B1 (enExample)
ES (1) ES2315307T3 (enExample)
GT (1) GT200100197A (enExample)
HN (1) HN2001000218A (enExample)
HU (1) HU227163B1 (enExample)
IL (1) IL138825A (enExample)
IS (1) IS2607B (enExample)
MX (1) MXPA03002612A (enExample)
NO (1) NO20031396L (enExample)
NZ (1) NZ525587A (enExample)
PA (1) PA8529801A1 (enExample)
PE (1) PE20020411A1 (enExample)
PL (1) PL365679A1 (enExample)
PT (1) PT1331935E (enExample)
SI (1) SI1331935T1 (enExample)
SK (1) SK4042003A3 (enExample)
TW (1) TWI270544B (enExample)
UA (1) UA75091C2 (enExample)
UY (1) UY26946A1 (enExample)
WO (1) WO2002028347A2 (enExample)
ZA (1) ZA200303113B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2550091A1 (en) * 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
WO2005082143A1 (en) * 2004-02-20 2005-09-09 Lifescape Biosciences Incorporated Compositions and methods for sleep regulation
WO2006135873A2 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. Parp modulators and treatment of cancer
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
EP2173344B1 (en) 2007-06-29 2016-04-06 Clarencew Pty Ltd. Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
JP5746615B2 (ja) * 2008-05-13 2015-07-08 エール ユニヴァーシティ 癌細胞への抗体の動員のためのキメラ小分子
JP6555884B2 (ja) 2011-05-31 2019-08-07 クラレンシュウ・プロプライエタリー・リミテッド 運動に関連する神経障害を予防および治療する方法
CA2853729A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
CN102816103B (zh) * 2012-08-20 2014-05-07 冉瑞琼 硫化天冬氨酸修饰的退黑素衍生物及其应用
EP3430022B1 (en) * 2016-03-14 2020-03-11 Somalogic, Inc. Compounds and methods for the synthesis of 5-(n-protected-tryptaminocarboxyamide)-2'-deoxyuridine phosphoramidite for incorporation into a nucleic acid sequence
CN116421600B (zh) * 2023-05-29 2024-08-23 重庆医科大学 色醇在制备治疗焦虑的药物中的应用
WO2025137730A1 (en) * 2023-12-22 2025-06-26 Alexander Shulgin Research Institute, Inc. N-substituted tryptamines and n-substituted lysergamides and their use as therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79264A0 (en) * 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US6310085B1 (en) * 1997-10-03 2001-10-30 Clarencew Pty Ltd. Method for the treatment of neurological or neuropsychiatric disorders
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders

Also Published As

Publication number Publication date
WO2002028347A3 (en) 2002-07-04
MXPA03002612A (es) 2004-04-02
IL138825A0 (en) 2001-10-31
PA8529801A1 (es) 2002-12-30
HUP0302616A2 (hu) 2003-11-28
HK1074163A1 (zh) 2005-11-04
CA2423628C (en) 2011-04-26
NO20031396D0 (no) 2003-03-27
CN1582147A (zh) 2005-02-16
EA200300436A1 (ru) 2003-10-30
CZ2003940A3 (cs) 2003-10-15
EE05192B1 (et) 2009-08-17
EP1331935B1 (en) 2008-10-01
SK4042003A3 (en) 2003-09-11
CY1110417T1 (el) 2015-04-29
HU227163B1 (en) 2010-09-28
KR100855385B1 (ko) 2008-09-04
UY26946A1 (es) 2001-11-30
US6780884B2 (en) 2004-08-24
DE60136003D1 (de) 2008-11-13
EA005918B1 (ru) 2005-06-30
EE200300135A (et) 2003-08-15
EP1331935A4 (en) 2004-12-01
CN100518735C (zh) 2009-07-29
PT1331935E (pt) 2009-01-19
CZ301098B6 (cs) 2009-11-04
UA75091C2 (en) 2006-03-15
HN2001000218A (es) 2002-05-09
IL138825A (en) 2006-06-11
CL2001002303A1 (es) 2010-06-25
KR20030051689A (ko) 2003-06-25
EP1331935A2 (en) 2003-08-06
AU9416201A (en) 2002-04-15
CA2423628A1 (en) 2002-04-11
US20050020664A1 (en) 2005-01-27
JP2004533986A (ja) 2004-11-11
AR035587A1 (es) 2004-06-16
PE20020411A1 (es) 2002-05-16
TWI270544B (en) 2007-01-11
NO20031396L (no) 2003-03-27
BG107759A (bg) 2004-01-30
CR6968A (es) 2004-02-25
GT200100197A (es) 2002-05-08
BR0114464A (pt) 2004-01-20
NZ525587A (en) 2005-03-24
PL365679A1 (en) 2005-01-10
US20040029950A1 (en) 2004-02-12
ES2315307T3 (es) 2009-04-01
WO2002028347A2 (en) 2002-04-11
SI1331935T1 (sl) 2009-04-30
DK1331935T3 (da) 2009-02-02
ZA200303113B (en) 2004-07-23
IS2607B (is) 2010-04-15
IS6752A (is) 2003-03-21

Similar Documents

Publication Publication Date Title
ATE478840T1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
ATE317260T1 (de) Pharmazeutische formulierungen mit platinderivaten
ATE355271T1 (de) Pharmazeutische zusammensetzung
ATE404180T1 (de) Geschmacksmaskierte pharmazeutische partikel
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
ITTO20010005A0 (it) Formulazione farmaceutica.
ATE320244T1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
DE60209929D1 (de) Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
NO20015670L (no) Forbedrede farmasöytiske formuleringer
EE05375B1 (et) LevosimendaniÁfarmatseutilineÁlahus
ATA59499A (de) Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
ATE409474T1 (de) Tryptamin-derivative und analoge verbindungen, und pharmazeutische formulationen daraus
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
IS2258B (is) Setin tríasóló-pýridasín afleiða, lyfjasamsetningar gerðar úr henni
DE60129238D1 (de) Pharmazeutische zusammensetzung
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE10084344T1 (de) Cyclosporin enthaltende pharmazeutische Zusammensetzung
EP1453502A4 (en) PHARMACEUTICAL FORMULATIONS WITH INDOLINONE DERIVATIVES
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20043007L (no) Farmasoytisk suspensjon for oral administrering
DE60126046D1 (de) Bizyklische Amino-Pyrazon Derivate, deren Herstellung und pharmazeutische Zusammensetzungen
IL154986A0 (en) Triazolo-epothilone derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
DE10291905D2 (de) Pharmazeutische Zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1331935

Country of ref document: EP